Literature DB >> 21536668

Neutral sphingomyelinase-2 mediates growth arrest by retinoic acid through modulation of ribosomal S6 kinase.

Christopher J Clarke1, Krutika Mediwala, Russell W Jenkins, Che A Sutton, Baby G Tholanikunnel, Yusuf A Hannun.   

Abstract

All-trans-retinoic acid (ATRA) induces growth arrest of many cell types. Previous studies have reported that ATRA can modulate cellular sphingolipids, but the role of sphingolipids in the ATRA response is not clear. Using MCF-7 cells as a model system, we show that ATRA stimulates an increase in ceramide levels followed by G(0)/G(1) growth arrest. Notably, induction of nSMase2 was the primary effect of ATRA on the sphingolipid network and was both time- and dose-dependent. Importantly, pretreatment with nSMase2 siRNA significantly inhibited ATRA effects on ceramide levels and growth arrest. In contrast, nSMase2 overexpression was sufficient to increase ceramide levels and induce G(0)/G(1) growth arrest of asynchronous MCF-7 cells. Surprisingly, neither ATRA stimulation nor nSMase2 overexpression had significant effects on classical cell cycle regulators such as p21/WAF1 or retinoblastoma. In contrast, ATRA suppressed phosphorylation of ribosomal S6 kinase (S6K) and its downstream targets S6 and eIF4B. Importantly, these effects were significantly inhibited by nSMase2 siRNA. Reciprocally, nSMase2 overexpression was sufficient to suppress S6K phosphorylation and signaling. Notably, neither ATRA effects nor nSMase2 effects on S6K phosphorylation required the ceramide-activated protein phosphatase PP2A, previously identified as important for S6K regulation. Finally, nSMase2 overexpression was sufficient to decrease translation as measured by methionine incorporation and analysis of polyribosome profiles. Taken together, these results implicate nSMase2 as a major component of ATRA-induced growth arrest of MCF-7 cells and identify S6K as a novel downstream target of nSMase2.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21536668      PMCID: PMC3122215          DOI: 10.1074/jbc.M110.193375

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  1,25-dihydroxyvitamin D3 and retonic acid analogues induce differentiation in breast cancer cells with function- and cell-specific additive effects.

Authors:  Q Wang; D Lee; V Sysounthone; S Christakos; R Korah; R Wieder
Journal:  Breast Cancer Res Treat       Date:  2001-05       Impact factor: 4.872

2.  Exogenous cell-permeable C6 ceramide sensitizes multiple cancer cell lines to Doxorubicin-induced apoptosis by promoting AMPK activation and mTORC1 inhibition.

Authors:  C Ji; B Yang; Y-L Yang; S-H He; D-S Miao; L He; Z-G Bi
Journal:  Oncogene       Date:  2010-08-30       Impact factor: 9.867

3.  Involvement of endogenous ceramide in the inhibition of telomerase activity and induction of morphologic differentiation in response to all-trans-retinoic acid in human neuroblastoma cells.

Authors:  Jacqueline M Kraveka; Li Li; Jacek Bielawski; Lina M Obeid; Besim Ogretmen
Journal:  Arch Biochem Biophys       Date:  2003-11-15       Impact factor: 4.013

4.  All-trans-retinoic acid: measurement of reference values in human serum by high performance liquid chromatography.

Authors:  A P De Leenheer; W E Lambert; I Claeys
Journal:  J Lipid Res       Date:  1982-12       Impact factor: 5.922

5.  Role for mammalian neutral sphingomyelinase 2 in confluence-induced growth arrest of MCF7 cells.

Authors:  Norma Marchesini; Walid Osta; Jacek Bielawski; Chiara Luberto; Lina M Obeid; Yusuf A Hannun
Journal:  J Biol Chem       Date:  2004-03-29       Impact factor: 5.157

6.  Expression of neutral sphingomyelinase-2 (NSMase-2) in primary rat hepatocytes modulates IL-beta-induced JNK activation.

Authors:  Alexander A Karakashian; Natalia V Giltiay; George M Smith; Mariana N Nikolova-Karakashian
Journal:  FASEB J       Date:  2004-04-01       Impact factor: 5.191

7.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B.

Authors:  D A Cross; D R Alessi; P Cohen; M Andjelkovich; B A Hemmings
Journal:  Nature       Date:  1995 Dec 21-28       Impact factor: 49.962

8.  Effects of TGF-beta 1 (transforming growth factor-beta 1) on the cell cycle regulation of human breast adenocarcinoma (MCF-7) cells.

Authors:  P Mazars; N Barboule; V Baldin; S Vidal; B Ducommun; A Valette
Journal:  FEBS Lett       Date:  1995-04-10       Impact factor: 4.124

9.  mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery.

Authors:  Do-Hyung Kim; D D Sarbassov; Siraj M Ali; Jessie E King; Robert R Latek; Hediye Erdjument-Bromage; Paul Tempst; David M Sabatini
Journal:  Cell       Date:  2002-07-26       Impact factor: 41.582

10.  The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress.

Authors:  Reuben J Shaw; Monica Kosmatka; Nabeel Bardeesy; Rebecca L Hurley; Lee A Witters; Ronald A DePinho; Lewis C Cantley
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-25       Impact factor: 11.205

View more
  14 in total

1.  Essential roles of neutral ceramidase and sphingosine in mitochondrial dysfunction due to traumatic brain injury.

Authors:  Sergei A Novgorodov; Christopher L Riley; Jin Yu; Keith T Borg; Yusuf A Hannun; Richard L Proia; Mark S Kindy; Tatyana I Gudz
Journal:  J Biol Chem       Date:  2014-03-21       Impact factor: 5.157

2.  Cardiac dysfunction in β-carotene-15,15'-dioxygenase-deficient mice is associated with altered retinoid and lipid metabolism.

Authors:  Seung-Ah Lee; Hongfeng Jiang; Chad M Trent; Jason J Yuen; Sureshbabu Narayanasamy; Robert W Curley; Earl H Harrison; Ira J Goldberg; Mathew S Maurer; William S Blaner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-09-26       Impact factor: 4.733

3.  ATRA transcriptionally induces nSMase2 through CBP/p300-mediated histone acetylation.

Authors:  Christopher J Clarke; Achraf A Shamseddine; Joseph J Jacob; Gabrielle Khalife; Tara A Burns; Yusuf A Hannun
Journal:  J Lipid Res       Date:  2016-03-24       Impact factor: 5.922

Review 4.  Ceramide-orchestrated signalling in cancer cells.

Authors:  Samy A F Morad; Myles C Cabot
Journal:  Nat Rev Cancer       Date:  2012-12-13       Impact factor: 60.716

5.  Off-target function of the Sonic hedgehog inhibitor cyclopamine in mediating apoptosis via nitric oxide-dependent neutral sphingomyelinase 2/ceramide induction.

Authors:  Marisa Meyers-Needham; Jocelyn A Lewis; Salih Gencer; R David Sentelle; Sahar A Saddoughi; Christopher J Clarke; Yusuf A Hannun; Haakan Norell; Telma Martins da Palma; Michael Nishimura; Jacqueline M Kraveka; Zohreh Khavandgar; Monzur Murshed; M Ozgur Cevik; Besim Ogretmen
Journal:  Mol Cancer Ther       Date:  2012-03-27       Impact factor: 6.261

Review 6.  Roles and regulation of neutral sphingomyelinase-2 in cellular and pathological processes.

Authors:  Achraf A Shamseddine; Michael V Airola; Yusuf A Hannun
Journal:  Adv Biol Regul       Date:  2014-10-27

Review 7.  Ribosomal Protein S6: A Potential Therapeutic Target against Cancer?

Authors:  Yong Weon Yi; Kyu Sic You; Jeong-Soo Park; Seok-Geun Lee; Yeon-Sun Seong
Journal:  Int J Mol Sci       Date:  2021-12-21       Impact factor: 5.923

8.  CXCR4-tropic, but not CCR5-tropic, human immunodeficiency virus infection is inhibited by the lipid raft-associated factors, acyclic retinoid analogs, and cholera toxin B subunit.

Authors:  Haruka Kamiyama; Katsura Kakoki; Sayuri Shigematsu; Mai Izumida; Yuka Yashima; Yuetsu Tanaka; Hideki Hayashi; Toshifumi Matsuyama; Hironori Sato; Naoki Yamamoto; Tetsuro Sano; Yoshihiro Shidoji; Yoshinao Kubo
Journal:  AIDS Res Hum Retroviruses       Date:  2012-08-27       Impact factor: 2.205

Review 9.  Sphingolipid metabolism and neutral sphingomyelinases.

Authors:  Michael V Airola; Yusuf A Hannun
Journal:  Handb Exp Pharmacol       Date:  2013

10.  Alkaline ceramidase 2 and its bioactive product sphingosine are novel regulators of the DNA damage response.

Authors:  Ruijuan Xu; Kai Wang; Izolda Mileva; Yusuf A Hannun; Lina M Obeid; Cungui Mao
Journal:  Oncotarget       Date:  2016-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.